- Home
- SSII vs IDYA Comparison
SSII vs IDYA Comparison
Compare SSII & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSII
- IDYA
- Stock Information
- Founded
- SSII N/A
- IDYA 2015
- Country
- SSII India
- IDYA United States
- Employees
- SSII N/A
- IDYA N/A
- Industry
- SSII
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- SSII
- IDYA Health Care
- Exchange
- SSII Nasdaq
- IDYA Nasdaq
- Market Cap
- SSII 1.5B
- IDYA 1.5B
- IPO Year
- SSII N/A
- IDYA 2019
- Fundamental
- Price
- SSII $10.13
- IDYA $18.18
- Analyst Decision
- SSII
- IDYA Strong Buy
- Analyst Count
- SSII 0
- IDYA 13
- Target Price
- SSII N/A
- IDYA $53.58
- AVG Volume (30 Days)
- SSII 51.4K
- IDYA 1.5M
- Earning Date
- SSII 05-14-2025
- IDYA 05-06-2025
- Dividend Yield
- SSII N/A
- IDYA N/A
- EPS Growth
- SSII N/A
- IDYA N/A
- EPS
- SSII N/A
- IDYA N/A
- Revenue
- SSII $20,649,528.00
- IDYA $7,000,000.00
- Revenue This Year
- SSII N/A
- IDYA $121.20
- Revenue Next Year
- SSII N/A
- IDYA $302.20
- P/E Ratio
- SSII N/A
- IDYA N/A
- Revenue Growth
- SSII 251.46
- IDYA N/A
- 52 Week Low
- SSII $0.32
- IDYA $13.45
- 52 Week High
- SSII $22.42
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- SSII N/A
- IDYA 48.15
- Support Level
- SSII N/A
- IDYA $16.82
- Resistance Level
- SSII N/A
- IDYA $21.43
- Average True Range (ATR)
- SSII 0.00
- IDYA 1.19
- MACD
- SSII 0.00
- IDYA -0.06
- Stochastic Oscillator
- SSII 0.00
- IDYA 29.65
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.